



RUTGERS
BIOMEDICAL AND
HEALTH SCIENCES

Management and Prevention of Opioid Withdrawal

Emily Gordon, MD

Assistant Professor of Medicine
Rutgers New Jersey Medical School
Department of Internal Medicine

Objectives

- Review signs/symptoms of opioid withdrawal
- Review COWS scoring system for opioid withdrawal
- Discuss opioid and non-opioid adjunctive medications for opioid withdrawal
- Discuss prevention of opioid withdrawal, including precipitated withdrawal
- Evaluate example patient cases

Definitions

- **Opioid withdrawal**: syndrome associated with the abrupt cessation, or decrease in dosage, of opioids by a patient who has physiologic dependence
- **Precipitated withdrawal**: withdrawal symptoms due to administration of an opioid antagonist or a partial opioid agonist to patient with physiologic dependence on opioids
- **Protracted withdrawal**: signs/symptoms of withdrawal persisting beyond the expected time frame for acute withdrawal, due to changes in neurocircuitry related to chronic opioid use

Signs and Symptoms of Opioid Withdrawal


- **Objective signs:**

- Diaphoresis
- Mydriasis
- Rhinorrhea
- Yawning
- Tremor, agitation
- Piloerection



Signs and Symptoms of Opioid Withdrawal, Continued

- Tachycardia
- Hypertension
- Vomiting
- Diarrhea



Symptoms of Opioid Withdrawal

- Dysphoric mood
- Irritability
- Insomnia
- Pain (generalized, localized, abdominal)
- Some may experience sedation

Serious Health Implications

- Hypertensive urgency/emergency
- CHF exacerbation due to increased sympathetic tone
- Preterm labor in pregnant women

COWS Scoring System



- Clinical Opiate Withdrawal Scale
- Classifies opioid withdrawal as mild, moderate, moderately severe or severe
- Based on pulse, diaphoresis, restlessness, pupil size, body pain, rhinorrhea/lacrimation, GI upset, tremor, yawning, anxiety/irritability, rhinorrhea
- Can be used to guide management of opioid withdrawal e.g. when to initiate buprenorphine

Management of Opioid Withdrawal

- Opioid agonists/partial agonists (preferred!)
 - Methadone
 - Buprenorphine
 - Opioid pain medications
- Non-opioid adjunctive medications (use only in addition to opioid agonists, unless contraindicated/patient preference)
 - Clonidine
 - Antiemetics
 - Antidiarrheals

Methadone

- Long acting opioid agonist used since 1960s as a treatment for OUD
- Multiple studies have demonstrated safety and efficacy in reducing heroin use, morbidity/mortality, spread of infection, and criminal justice utilization



Methadone, Continued

Advantages

- Easier to initiate than buprenorphine as no risk of precipitated withdrawal
- Does not interfere with opioid pain medications

Disadvantages

- Multiple drug interactions
- QT prolongation (though increased risk of torsades is controversial)
- Does not protect against overdose
- Requires follow up in a methadone clinic

Methadone, Continued

- Starting dose is 20 – 30mg PO daily
- Dividing doses may provide better analgesic effects
- Titrate up every 3-4 days until improvement in cravings (withdrawal symptoms should resolve with lower dose)

Buprenorphine

- Partial μ -receptor agonist
- SL tabs/films
- Start with a dose of 2-4mg of buprenorphine when patient exhibits mild-moderate withdrawal
 - Take 2-4mg every 2 hours as needed for a maximum dose of 16mg on day 1
- On day 2, take the total daily dose of day 1 and may divide the dose. Patient can take up to a maximum dose of 24mg on day 2.
- Steady state may take 5-7 days



Adjunctive Therapies for Opioid Withdrawal

Withdrawal Symptom	Therapy Options
Diarrhea	Loperamide
Nausea	Ondansetron, Metoclopramide
Anxiety, irritability, Diaphoresis	Clonidine
Insomnia	Diphenhydramine, Trazodone
Pain	APAP/ NSAIDs

Prevention of Opioid Withdrawal

- Continue opioid agonist therapy when possible
 - Hospitalization is a great opportunity to start methadone or buprenorphine in patients with untreated OUD
 - Go low/slow when starting buprenorphine in patients already in mild withdrawal
 - Micro-dosing circumvents need to await withdrawal prior to starting buprenorphine

Buprenorphine Microdosing

Table 1. Buprenorphine Microdosing Protocol Used by Our Team

Day	Buprenorphine dosage	Methadone dose
1	0.5 mg ^a SL once/day	Full dose
2	0.5 mg ^a SL twice/day	Full dose
3	1 mg SL twice/day	Full dose
4	2 mg SL twice/day	Full dose
5	4 mg SL twice/day	Full dose
6	8 mg SL once/day	Full dose
7	8 mg SL in A.M. and 4 mg SL in P.M.	Full dose
8	12 mg SL/day	Stop

SL = sublingually.

^aFor our buprenorphine formulation, one-quarter of a 2-mg sublingual strip was used.

Table 3. Protocol Use in Patient 2

Protocol day	Buprenorphine total daily dose, mg	Methadone total daily dose, mg	Maximum pain score, 0–10
0	0	100	7
1	1.0	100	8
2	1.5	100	6
3	3	100	8
4	6	100	7
5	8	100	8
6	8	100	8
7	12	100	6
8	16	0	6
9	16	0	8
10	20	0	8
11	24	0	6

Prevention of Opioid Withdrawal, Continued

- Discontinuing buprenorphine no longer thought to be necessary perioperatively/for acute pain requiring full opioid agonists
 - Most studies show adequate analgesia from opioid agonists is possible for patients taking 16mg or less buprenorphine/day
 - Continuation of buprenorphine decreases risk of relapse

Goel A et al. The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes. *Can J Anaesth.* 2019 Feb; 66(2): 201-217.

Examples

1. 54 year old male with hypertension, opioid use disorder, tobacco use admitted after motor vehicle accident with left femur fracture requiring internal fixation. Post-operative day #1, patient complains of diffuse pain, diarrhea, and irritability. Left leg pain is partially controlled on a Dilaudid PCA.
 - **How do you differentiate between post-operative pain and opioid withdrawal?**
 - **How would you treat opioid withdrawal in this patient?**

Examples

2. 42 year old female with opioid use disorder and gallstones admitted with acute pancreatitis. Patient is on Suboxone 8-2mg, 1 film SL BID for many years without relapse. Patient complains of severe epigastric/back pain.
 - **Do you continue Suboxone in this patient?**

MAT NJ Centers of Excellence Contact Information

Northern: COE@njms.rutgers.edu

Southern: SouthernNJCOE@rowan.edu

MAT PROVIDER HOTLINE

866-221-2611

(Monday-Friday, 8am-8pm)

PLEASE DIRECT ALL FEEDBACK FOR THE PRESENTATION TO
COE@NJMS.RUTGERS.EDU. ALL FEEDBACK IS GREATLY APPRECIATED.